Next Article in Journal
Influence of Hematocrit and Total-Spot Volume on Performance Characteristics of Dried Blood Spots for Newborn Screening
Previous Article in Journal
Improved Identification of Partial Biotinidase Deficiency by Newborn Screening Using Age-Related Enzyme Activity Cutoffs: Reduction of the False-Positive Rate
Article Menu

Export Article

Open AccessReview
Int. J. Neonatal Screen. 2015, 1(2), 57-68; doi:10.3390/ijns1020057

Newborn Screening for Glutaric Aciduria Type I: Benefits and limitations

University Children's Hospital Heidelberg, Clinic 1, Division of Neuropediatrics and Metabolic Medicine, 69120 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Ralph Fingerhut
Received: 22 April 2015 / Revised: 26 June 2015 / Accepted: 30 June 2015 / Published: 10 July 2015
View Full-Text   |   Download PDF [251 KB, uploaded 10 July 2015]

Abstract

More than 15 years ago glutaric aciduria type I has been included in newborn screening programmes and pilot studies evaluating the potential benefit of early diagnosis and start of metabolic treatment for patients with this disease have been initiated. At that time many important questions on epidemiology, diagnostic quality, natural history, treatment, and cost effectiveness were not sufficiently answered. In particular, it was rather unknown whether early treatment improves the outcome. After implementation of glutaric aciduria type I in an increasing number of countries, and with careful evaluation of disease course and impact of early treatment, there is now solid evidence that affected individuals do have substantial benefit and that newborn screening for this disease is a cost-effective diagnostic intervention. Despite this success, there are still limitations concerning diagnostic sensitivity for patients with a low excreting phenotype and knowledge on long-term disease outcome. In conclusion, it has become evident that tandem mass spectrometry-based newborn screening for glutaric aciduria type I is a powerful and cost-effective tool to prevent the manifestation of prognostically-relevant movement disorders in the majority of early diagnosed patients. View Full-Text
Keywords: glutaric aciduria type I; newborn screening; tandem mass spectrometry; glutarylcarnitine; guideline; cost-effectiveness glutaric aciduria type I; newborn screening; tandem mass spectrometry; glutarylcarnitine; guideline; cost-effectiveness
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Heringer, J.; Boy, N.; Burgard, P.; Okun, J.G.; Kölker, S. Newborn Screening for Glutaric Aciduria Type I: Benefits and limitations. Int. J. Neonatal Screen. 2015, 1, 57-68.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Neonatal Screen. EISSN 2409-515X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top